Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”

A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol... Adv Ther https://doi.org/10.1007/s12325-023-02495-0 LETTER A Response to: Letter to the Editor Regarding ‘‘Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis’’ . . . . Afisi S. Ismaila Katrin Haeussler Mia Malmena¨s Raj Sharma . . . Chris Compton Claus F. Vogelmeier MeiLan K. Han David M. G. Halpin Received: January 31, 2023 / Accepted: March 9, 2023 The Author(s) 2023 Keywords: COPD; Fixed-effects model; (NMA) of fluticasone furoate/umeclidinium/ Fluticasone furoate/umeclidinium/vilanterol; vilanterol (FF/UMEC/VI) triple therapy com- Heterogeneity; Indirect treatment comparison; pared with other therapies for the treatment of Network meta-analysis; Random effects model; chronic obstructive pulmonary disease (COPD) Triple therapy [1]. To minimize clinical heterogeneity across COPD studies, we conducted two separate Dear Editor, NMAs [1, 2] and presented the data in parallel in the same journal. The dual therapy NMA [2] We would like to thank you for allowing us the included studies from patients who were mostly opportunity to respond to the letter received symptomatic with infrequent exacerbations to from Marshall et al. and to address the queries ensure that the long-acting b -agonist (LABA)/ raised with respect to our network meta-analysis long-acting muscarinic antagonist (LAMA) C. F. Vogelmeier http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”

Loading next page...
 
/lp/springer-journals/a-response-to-letter-to-the-editor-regarding-fluticasone-furoate-iB7WmHEMcM

References (25)

Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2023
ISSN
0741-238X
eISSN
1865-8652
DOI
10.1007/s12325-023-02495-0
Publisher site
See Article on Publisher Site

Abstract

Adv Ther https://doi.org/10.1007/s12325-023-02495-0 LETTER A Response to: Letter to the Editor Regarding ‘‘Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis’’ . . . . Afisi S. Ismaila Katrin Haeussler Mia Malmena¨s Raj Sharma . . . Chris Compton Claus F. Vogelmeier MeiLan K. Han David M. G. Halpin Received: January 31, 2023 / Accepted: March 9, 2023 The Author(s) 2023 Keywords: COPD; Fixed-effects model; (NMA) of fluticasone furoate/umeclidinium/ Fluticasone furoate/umeclidinium/vilanterol; vilanterol (FF/UMEC/VI) triple therapy com- Heterogeneity; Indirect treatment comparison; pared with other therapies for the treatment of Network meta-analysis; Random effects model; chronic obstructive pulmonary disease (COPD) Triple therapy [1]. To minimize clinical heterogeneity across COPD studies, we conducted two separate Dear Editor, NMAs [1, 2] and presented the data in parallel in the same journal. The dual therapy NMA [2] We would like to thank you for allowing us the included studies from patients who were mostly opportunity to respond to the letter received symptomatic with infrequent exacerbations to from Marshall et al. and to address the queries ensure that the long-acting b -agonist (LABA)/ raised with respect to our network meta-analysis long-acting muscarinic antagonist (LAMA) C. F. Vogelmeier

Journal

Advances in TherapySpringer Journals

Published: Apr 1, 2023

Keywords: COPD; Fixed-effects model; Fluticasone furoate/umeclidinium/vilanterol; Heterogeneity; Indirect treatment comparison; Network meta-analysis; Random effects model; Triple therapy

There are no references for this article.